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Abstract
Background: Targeting the expression of genes has emerged as a potentially viable therapeutic approach to
human disease. In Alzheimer’s disease, therapies that silence the expression of tau could be a viable strategy to
slow disease progression.
Methods: We produced a novel strain of transgenic mice that could be used to assess the efficacy of gene
knockdown therapies for human tau, in live mice. We designed a tetracycline-regulated transgene construct in
which the cDNA for human tau was fused to ubiquitin and to luciferase to create a single fusion polyprotein,
termed TUL.
Results: When expressed in brain, the TUL polyprotein was cleaved by ubiquitin-processing enzymes to release the
luciferase as an independent protein, separating the half-life of luciferase from the long-lived tau protein. Treatment
of bigenic tTA/TUL mice with doxycycline produced rapid declines in luciferase levels visualized by in vivo imaging
and ex vivo enzyme measurement.
Conclusions: This new mouse model can be used as a discovery tool in optimizing gene targeting therapeutics
directed to reduce human tau mRNA levels.
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Background
Mutations in tau cause familial frontotemporal dementia
(FTD-tau) and aggregates of wild-type tau are a preva-
lent pathology of Alzheimer’s disease (AD) and other
sporadic tauopathies [1]. Although tau has clearly been a
target of interest in these diseases, there have been
relatively few good leads for small molecule therapeutics
to reduce tau pathology and slow disease progression.
Dominantly inherited familial neurodegenerative dis-
eases, such as FTD, are prime candidates for biologic
therapies (biotherapies) in which expression of the
mutant gene is directly targeted by gene silencing
approaches. Multiple approaches to knocking down
mutant gene expression have been described in the
literature including viral vector delivery of shRNAi or
microRNA mimics, delivery of naked RNAi and RNAi
complexed with various reagents to facilitate uptake, and
delivery of modified antisense DNA oligonucleotides
(ASOs) [2–5]. Preclinical testing of such therapies has
met with encouraging outcomes, with examples of
good to moderate efficacy [6–9].
The accumulation of misfolded tau appears to correl-
ate well with disease progression in human AD [10] and
there are ample data to suggest that patients with high
amyloid burden and mild memory impairment would be
high risk for subsequent development of tauopathy and
further degeneration [11, 12]. Second, the clinical course
of AD is relatively slowly progressing, offering a larger
window for therapeutic intervention. Third, familial
cases of FTD-tau present a highly motivated patient
population in which silencing mutant tau expression
would appear to be a highly relevant target. Further-
more, FTD represents a particularly attractive target for
gene knockdown as it may be possible to direct such
* Correspondence: jada.lewis@ufl.edu; drb1@ufl.edu
1Department of Neuroscience, Center for Translational Research in
Neurodegenerative Disease, University of Florida, Gainesville, FL, USA
Full list of author information is available at the end of the article
© 2016 The Author(s). Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0
International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and
reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to
the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver
(http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
Fromholt et al. Alzheimer's Research & Therapy  (2016) 8:36 
DOI 10.1186/s13195-016-0202-1
strategies against a specific isoform of tau [four repeat
(4R)] which is either elevated or preferentially aggre-
gated in many cases of the familial disease [13]. Fourth,
although multiple anti-amyloid therapies have reached
the human clinic (with limited success so far), the pipe-
line for modulators of tau biology has been limited
[12, 14, 15]. Thus, despite the hurdles created by the
need to use invasive procedures to deliver these thera-
peutics and the difficulties in assessing target engage-
ment in human trials, there is a strong rationale for
pursuing gene-silencing therapies for tau in FTD and
possibly AD.
In FTD cases caused by mutations in tau, it might be
possible to use allele-specific targeting to diminish the
levels of mutant tau. Such strategies might be very ef-
fective in cases involving mutations that alter tau spli-
cing. In AD cases, however, there are no mutations or
obvious splicing alterations and thus a gene silencing ap-
proach would target wild-type tau. A recent study to tar-
get tau expression in adult mice has demonstrated the
potential efficacy of antisense-oligonucleotide gene-
silencing approaches and demonstrated that reductions
of tau in the adult nervous system may not produce ad-
verse effects [16]. However, it should be noted that
humans that are heterozygous for a microdeletion of
chromosome 17, which includes the MAPT locus and at
least two other genes, have multiple developmental de-
fects including mental retardation [17]. Mice lacking
Mapt have been reported to show defects in neuronal
migration [18], and defects in long-term potentiation
have been reported in both knockout mice and slice cul-
tures from adult rats treated with tau shRNAi [19]. Al-
though these data suggest a potential for tau-silencing
therapies to produce adverse effects in humans, mice
with heterozygous or homozygous deletions of tau are
cognitively normal, and partial or complete elimination
of tau in mice that overproduce human Aβ has been
shown to ameliorate Aβ-mediated cognitive deficits [20].
Thus, a gene silencing approach to tau may well be a vi-
able therapeutic strategy for multiple human tauopa-
thies, including AD.
In the present study, we have endeavored to create a
new transgenic mouse model expressing the human 4R
tau that is designed for the sole purpose of optimizing
gene silencing therapies for tau. Optimizing the type of
therapeutic, the dose, and the route of delivery for each
of these potential therapies in vivo typically involves
cross-sectional studies that provide a snapshot of effi-
cacy at whatever times are chosen to sacrifice animals
and analyze tissues. In order to more effectively assess
the efficacy of these types of therapeutics in vivo, we de-
signed and generated transgenic animals that encode hu-
man 4R tau, containing the P301L mutation which is
associated with FTD, that is fused in-frame to luciferase
for the purpose of generating transgenic mice that could
be used to report the efficacy of knockdown therapeutics
in a mouse model of tauopathy. By placing the human
tau transgene under the control of a doxycycline
(Dox) suppressible promoter, we built in an internal
positive control into this transgenic model. We dem-
onstrate the utility of this model and the dynamic
range of the luciferase reporter as an in vivo indicator
of gene expression.
Methods
Generation of transgenic mice
Transgenic animals were created from transgene vectors
based on the tetPrP.Xho vector [21, 22]. First, we
constructed a cDNA that sequentially encodes tau-
ubiquitin-luciferase as a contiguous gene (Fig. 1). The
tau gene is a human cDNA for 0N4R tau that encodes
the P301L mutation. This cDNA has been expressed in
mice previously [23]. The cDNA for ubiquitin is derived
from human and the cDNA for luciferase is derived
from firefly (Phontinus pyralis). The fused cDNA was
generated by polymerase chain reaction (PCR)-based
methods that amplified each of these genes independ-
ently using primers that produced novel restriction
endonuclease sites to enable stitching the gene together
to create a single open-reading-frame for a poly-protein
that we abbreviated as TUL.
After linearizing the vector plasmid with Not1 en-
zymes that separate the bacterial plasmid sequences
from the promoter element and tetPrP.Xho vector se-
quences, the transgene DNA fragment was purified by
agarose gel electrophoresis and injected into fertilized
embryos from FVB/NJ mice in the University of Florida
Mouse Modeling Core. From these injections, two foun-
ders were identified by PCR of the genomic DNA ex-
tracted from tail biopsy by standard methods of
proteinase K digestion, high salt precipitation, and etha-
nol precipitation. The PCR protocol used was as follows:
ddH2O 20.7 μL, 10X PCR buffer (w/MgCl2) 2.5 μL,
5 mM dNTPs 0.5 μL, 50 μM PrP-AS (antisense primer
-5′-CCA AGC CTA GAC CAC GAG AAT GC-3′),
50 μM TUL-S (sense primer – 5′-CAA ATT GTA ACT
CGA TCA GGC CCC TGG GGC GGT-3′), Taq DNA
Polymerase (New England Biolabs, Ipswich, MA, USA)
0.1 μL, Tail DNA 1 μL. The PCR program used was as
follows: 94 °C for 30 s, 55 °C for 60 s, 72 °C for 3 m, 35 cy-
cles, followed by 72 °C for 10 min then hold at 10 °C.
One of these founders efficiently transmitted the
transgene to offspring, producing a line termed Y-74.
Mice from this line were crossed to mice that express
the tet-Transactivator (tTA) under the CamKIIα pro-
moter [24] [B6.Cg-Tg(Camk2a-tTA)1Mmay/Dbo, Jackson
Laboratories, Bar Harbor, ME, USA], which had been
backcrossed to FVB/NJ mice twice. Mice bigenic for
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CamKII-tTA and tet.TUL were expected to express the
transgene exclusively in the forebrain.
All procedures involving mice were reviewed and ap-
proved by the University of Florida Animal Care and
Use Committee. The mice described here are available
through the Jackson Laboratories.
Immunoblotting
To detect transgenic human tau expression in brain,
mice were deeply anesthetized and then perfused with
ice-cold PBS. The brains were then quickly removed and
the forebrains were dissected and flash frozen on dry ice.
To homogenize the brain, the tissue was sonicated, using
an ultrasonic probe (Misonix microson ultrasonic cell
disrupter XL, Farmingdale, NY USA) at an intensity set-
ting of 2. Each brain was sonicated three times for 10 s
each in 1× PBS (phosphate-buffered saline) containing
1:100 v/v protease inhibitor cocktail (Sigma, St. Louis,
MO, USA). The tissue homogenate was centrifuged at
17,000 × g for 5 min to produce a clarified brain hom-
ogenate. The protein concentrations of the resulting ho-
mogenates were then determined by bicinchoninic acid
assay, as described by the manufacturer (Pierce Biotech-
nology/Thermo Fisher, Waltham, MA, USA). Fifty mi-
crograms of each brain homogenate were mixed with 2×
Laemmli sample buffer and boiled for 5 min. Sample
buffers contained β-mercaptoethanol to reduce any
disulfide bonds and the samples were electrophoresed
in 4–20 % Tris-Glycine sodium dodecyl sulfate-poly-
acrylamide gels (Invitrogen Life Technologies, Grand Is-
land, NY, USA). Following transfer to nitrocellulose
membranes (Amersham/GE Healthcare Life Sciences,
Pittsburgh, PA, USA), the membranes were blocked in
5 % milk in PBS-T (1X PBS, 0.1 % Tween-20) for 1 h, then
incubated for 2 h at room temperature with the mouse
monoclonal antibody Tau 13 (Covance, Princeton, NJ,
USA) at 1:4000 in PBS-T and 5 % milk. The membrane
was then washed with PBS-T, then incubated for 1 h at
room temperature with a goat-mouse secondary antibody
(KPL, Gaithersburg, MD, USA) at 1:5000 in PBS-T and
5 % milk before developing with enhanced chemilumin-
escence reagents (Thermo Scientific Inc., Rockford,
IL, USA) and visualizing with a FluorChem E imager
(Protein Simple, Santa Clara, CA, USA).
Imaging
For in vivo imaging of the bigenic tTA/TUL mice, we
used the Perkin Elmer IVIS Spectrum In Vivo System
(Xenogen Biosciences Perkin Elmer, Waltham, MA,
USA). Mice were placed under deep anesthesia and were
first imaged prior to injection with luciferin. Mice were
then injected with 100 μL of 30 mg/mL XenoLight
Rediject D-luciferin Ultra (Xenogen Biosciences Perkin
Elmer, Waltham, MA, USA). Images were obtained on
the IVIS imager from 6 min after injection (peak signal
was previously determined at approximately 12 min after
injection of luciferin). During every scan, images were
taken at the same exposure setting (determined by the
IVIS imager during the first scan) and multiple images
were captured to insure that the peak signal had been
reached. To quantify the bioluminescence for each ani-
mal, we used Living Image Analysis software (Xenogen
Biosciences Perkin Elmer, Waltham, MA, USA). With
this software, a box was drawn around the area of signal
in the region of the head to define a region of interest
(ROI). The area of the ROI for each mouse within the
Fig. 1 Expression of tau in bigenic tTA/TUL-Y74 mice. The diagram above the figure depicts the expected mRNA for the transgene and its
products (not precisely to scale). The cDNA for the transgene construct was designed to encode 156 bp of 5′ untranslated sequence and 1227 bp
of 3′ untranslated sequence from the human tau gene, providing additional targeting options for knockdown. The levels of tau in the forebrains
of two tTA/TUL mice (aged 2 months) are compared to that of Tg4510 P301L tau mice (aged 3 months) and iP301L tau mice (aged 24 months),
which express human tau from the same cDNA used in the TUL mice. The blots were probed with a mouse monoclonal antibody that
specifically reacts with human tau (clone Tau-13). The tau protein created by processing of the TUL poly-protein would be expected to possess a
C-terminal ubiquitin moiety and thus migrate to a slightly higher molecular weight
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same image was equal. The average radiance within the
ROI was measured and compared.
Ex vivo assessment of luciferase activity
Brains were harvested from mice as described above and
stored at −80 °C. To prepare lysates, the brains were
weighed and then homogenized in PBS (10 volumes
relative to mass) as described above to produce a 10 %
homogenate. The PBS contained protease inhibitor
[1 μL of SIGMA protease inhibitor cocktail (catalog
number: P8340-5ML; Sigma-Aldrich, St. Louis, MO,
USA) for every 99 μL of PBS 1×]. The mass of the PBS
1× buffer with protease inhibitor was approximated
volumetrically by assuming a density of 1 mg/μL at
room temperature. To detect luciferase activity, 10 and
20 μL of each sample were dispensed to separate wells
in an opaque 96 well plate and 40 and 30 μL of PBS 1×
were added to the wells, respectively. Fifty microliters of
luciferase substrate solution from the Promega Bright-
Glo Luciferase Assay System (catalog number: E2610,
Madison, WI, USA) were then added to each well and
luminescence values were immediately collected by a
plate reader (Biotek Synergy HT Microplate Reader,
Winooski, VT, USA).
Results
Mice from the Y-74 line of TUL mice were crossed to
mice that express the tet-Transactivator (tTA) under the
CamKIIα promoter to produce mice that exclusively ex-
press the TUL construct in forebrain. From the design of
the construct, the expectation is that human tau proteins
present in these mice would have C-terminal fusion of
ubiquitin. Immunoblots of brain homogenates from
these mice confirmed the expression of tau with the tau
protein migrating at a slightly larger size relative to mice
express human tau alone (Fig. 1). The molecular size of
firefly luciferase is 550 amino acids – predicted relative
molecular weight of 55 kDa. Uncleaved TUL protein
would be predicted to migrate at more than 130 kDa.
Thus, the tau protein in the TUL mice appears to mi-
grate to a size that would be expected if the luciferase
had been cleaved by ubiquitin processing enzymes as
envisioned in the design of the construct. Notably, the
levels of Tau-Ubq in these mice were lower than the
levels detected in two other lines of mice that express
human Tau (Tg4510 and iP301L [23]) used here is as
positive controls. The responder line of Tg4510 mice is
one of the two transgenes that is expressed in the previ-
ously described rTg4510 model [23]. In the absence of
the tTA transgene, Tg4510 mice express low levels
(approximately twofold) of mutant human tau and do
not develop tau pathology [23]. The iP301L model is a
bigenic model similar to the rTg4510 model that is
bigenic for a mutant tau responder transgene and
CamKIIα-tTA, resulting in levels of human tau expres-
sion that are approximately seven-fold higher than en-
dogenous mouse tau. The levels of mutant human tau in
the bigenic tTA/TUL-Y74 mice are lower than that of
the Tg4510 responder line and thus would appear to be
below the threshold to produce tau pathology.
To determine the utility of these new mice for in vivo
imaging, we injected bigenic tTA/TUL mice that were
aged 6–7.5 months with the luciferase substrate lucif-
erin. When imaged in an IVIS imaging device, we easily
detected bioluminescence in brain (Fig. 2a and b). The
levels of luciferase were relatively steady in repeated
measures of bioluminescence (Fig. 2c – solid black line)
and much higher than the levels transgenic only for the
TUL gene (Fig. 2c).
In using the tet-PrP.Xho vector to express the TUL
construct, we gained two major advantages that make
the technology more useable. First, by using CamKII-
tTA to drive expression of TUL, we express the protein
exclusively in the forebrain and eliminate a potential
issue with bioluminescence signal that could come from
other sources if the gene were more broadly expressed.
Fig. 2 Bioluminescence in bigenic tTA/TUL-Y74 mice. a Baseline
images of three mice of three different genotypes prior to luciferin
injection. b Images of three mice of three different genotypes 10–12
min after luciferin injection. c Graphs of bioluminescence units in
bigenic tTA/TUL-Y74 mice that were either given food containing
Dox at day 0 or left untreated. The mice were re-injected and
re-imaged at 7, 14, 21, and 28 days. Dox treatment produced
sustained suppression of bioluminescence
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Second, we created the possibility for very nice positive
controls because the expression of the TUL construct
should be suppressed by feeding the mice Dox [21, 23, 24].
To confirm the utility of the model, we conducted a study
in which bigenic tTA/TUL mice were followed longitudin-
ally (Fig. 2c, dashed black line). The mice were injected
with luciferin, imaged, and put on feed that contains Dox.
After 7 days, the mice were imaged again, with repeated
imaging at regular intervals. Within the first 7 days, the
level of bioluminescence fell by 90 % and remained low as
long as the mice were on Dox (re-imaged at 7, 21, and
28 days). When the same mice were put back on regular
feed, the levels of brain bioluminescence after injection
with luciferin quickly increased (not shown). Together,
these data demonstrate that levels of luciferase activity, as
measured by in vivo bioluminescence, fall as one would
predict after transgene expression is suppressed.
To confirm the bioluminescence data, we performed
ex vivo analyses of luciferase levels in tissue extracts
from these mice (Fig. 3). Brains harvested from mice
were homogenized in PBS (10 % weight/volume) and
small portions of this homogenate (10 and 20 μL) were
assayed for luciferase activity. As expected, the levels of
bioluminescence generated by homogenates of NTg and
TUL mice lacking the tTA gene were very low (in this
assay both were below the level of detection) (Fig. 3a).
By contrast, bioluminescence was easily detected in ho-
mogenates from tTA/TUL mice with the levels dropping
by 90 % in homogenates prepared from animals fed diets
containing Dox (Fig. 3a).
To determine the levels of tau, a portion of these same
brain homogenates was analyzed by immunoblot for tau
(Fig. 3b), comparing mice on normal diets to mice that
had been on the Dox diet for 7 days. From studies of the
rTg4510 model of inducible tau expression, we expected
that the levels of tau in mice fed Dox might not decline
quickly due to the long in vivo half-life of tau (~11 days)
[25]. As expected, immunoblots of these tissue homoge-
nates showed that tau protein persisted longer than the lu-
ciferase protein, derived from the same mRNA (Fig. 3b).
The blots revealed a substantial number of what appear to
be breakdown products of the tau that may be a conse-
quence of the presence of the c-terminal ubiquitin moiety
that is fused to the tau sequence of the polyprotein (see
Fig. 1). These data show that luciferase activity provides a
much better report of transgene expression levels than the
long lived tau protein. These data also reinforce the idea
that significantly reducing steady-state tau levels will re-
quire sustained suppression of tau expression [23, 25].
Discussion
Although is it quite feasible to determine the efficacy of
gene knockdown in mouse models by directly assessing
the levels of gene products, either mRNA or protein, the
analysis of gene expression in the central nervous system
(CNS) cannot be done in a longitudinal manner. For
studies in which the goal is to optimize treatment regi-
mens with gene silencing therapeutics, an ability to lon-
gitudinally assess target engagement in living animals
would save both time and expense. Here, we describe
the generation of transgenic mice expressing a tau-
luciferase reporter built expressly for such a purpose.
We included in the design of the model, the use of
tetracycline-analog-responsive transgene vectors as a
means to produce a positive control and assess the dy-
namic range of the luciferase reporter. Here we demon-
strate the following: (1) the generation of a line of mice that
Fig. 3 Ex vivo analysis of Luciferase and tau levels. The forebrains of
bigenic and single transgenic mice (n = 3 each genotype) were
homogenized in PBS (10 % weight/volume). a Two different
amounts of each homogenate were assayed for luciferase activity as
described in “Methods.” Only the bigenic tTA/TUL mice produced
high levels of luciferase activity. Bigenic tTA/TUL mice fed chow
containing Dox produced 90 % less luciferase activity. The error bar
estimates standard deviation. b Immunoblot of brain homogenates
for tau with a monoclonal antibody that specifically reacts with
human tau (clone Tau-13). The brain homogenates of three different
tTA/TUL mice (no Dox) and three different tTA/TUL mice fed Dox
chow for 7 days, along with non-transgenic brain homogenates and
mice transgenic for only the TUL responder transgene were analyzed.
Each lane contains 50 μg of total protein
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express a tau-ubiquitin-luciferase fusion construct from a
single mRNA; (2) the processing of this fusion protein to
produce a tau protein that migrates to a size closely ap-
proximating the expectation for a tau-ubiquitin fusion pro-
tein; (3) high levels of bioluminescence in the brains of
these mice when the tet-transactivator is co-expressed; (4)
rapid decline in bioluminescence when transgene expres-
sion is silenced. Thus, this new model has several attributes
that one would like to have in a model that is used to test
gene silencing therapies targeting human tau.
We envision using this model to assess the efficacy of
gene silencing therapies that target the gene at the level of
the mRNA, such as ASOs, siRNA, and viruses encoding
shRNAs. The model may also be useful in assessing ther-
apies that target exonic sequences in the DNA directly,
such as viruses encoding CRISPR/Cas9 targeting elements.
Because the promoter elements that drive expression of
the transgene are not derived from tau, the model cannot
be used to screen drugs that specifically target transcrip-
tional regulators of tau. Moreover, the model would not
be particularly useful in screening drugs that target tau
protein degradation. However, with a redesign of the
cDNA, eliminating the ubiquitin element so that tau and
luciferase remain attached as a fusion protein, it would be
possible to create mice that could report tau protein levels.
The model in its current form is also not appropriate for
screening ASOs that would be designed to modulate spli-
cing of tau pre-mRNA. However, with minimal re-
designed an intron could be added to the construct to en-
able assessments of ASO efficacy in modulating splicing.
This new model provides proof-of-concept demonstration
of a means to produce a luciferase reporter mouse in
which luciferase is expressed from an mRNA encoding
tau while at the same time having the half-life of luciferase
separated from the long-lived tau protein [25]. From prior
studies of mice expressing tau from tetracycline-regulated
vectors similar to what we have used here, we knew that
the levels of transgene expressed tau mRNA fall rapidly
when mice are treated with Dox [23]. The rapid decline in
luciferase levels in the Dox-treated mice demonstrates
that luciferase activity in this model is a good indicator of
mRNA levels. Indeed, the rapid decline in biolumines-
cence activity in the bigenic tTA/TUL mice after sup-
pressing transgene expression with Dox is typical for
short-lived CNS proteins. For example, the levels of trans-
gene expressed amyloid precursor protein in a tet-
regulated model decline rapidly after mice are given food
containing Dox [21]. Our data show that engineering an
efficiently-cleaved proteolytic site between the target gene
and luciferase provides an effective means to separate a lu-
ciferase reporter from a co-expressed gene of interest in
vivo.
When we originally conceived of the transgene con-
struct, we had some aspirations that the level of tau that
would be produced by the TUL construct might rise to
the level required to produced tau-mediated neurodegen-
eration, ultimately enabling a better prediction regarding
the level of gene suppression that might be required to
attenuate pathology. In hindsight, we now believe that ab-
sence of neurodegeneration in this model may be advanta-
geous because neuronal loss would almost certainly cause
the levels of luciferase to fall as cells expressing the trans-
gene die. Studies in tetracycline-regulated tau mice have
already demonstrated that silencing tau expression can be
beneficial and that early intervention may be critical [23].
Our TUL mice provide a new approach to screen and
optimize tau-silencing therapeutics that enables longitu-
dinal assessments of target-engagement.
Conclusions
In summary, we describe the production of a new model
of human tau expression that we envision to be used in
longitudinal assessment of tau-silencing therapeutics. In
light of the current paucity of drug targets that could
slow the progressive misfolding of tau as occurs in AD
and other tau pathologies, targeting the production of
tau has emerged as an attractive approach. The long
half-life of the tau protein may be a serious barrier to
this approach, requiring early intervention, but such a
therapeutic paradigm may provide a ray of hope to pa-
tients at high risk of developing disease because they
harbor disease-causing mutations in tau. Ultimately, as
gene silencing therapeutics for CNS diseases move into
the clinic with greater frequency, the risk-reward calcu-
lations for this invasive therapy may improve to the
point of wider deployment in patients at high risk for all
diseases in which tau pathology features prominently,
such as AD.
Abbreviations
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protein tau-ubiquitin-luciferase
Acknowledgements
The authors are grateful to the University of Florida Mouse Modeling Core
for their assistance in generating the mice and to the University of Florida
Animal Care staff for supporting the housing of the mice.
Funding
This work was supported by a grant from the National Institutes of Neurological
Disorders and Stroke (R21NS077032 to DRB and JL), the BrightFocus Foundation
(A2015688S to JL), and by the SantaFe HealthCare Alzheimer’s Disease Research
Center.
Availability of supporting data
Not applicable.
Authors’ contributions
JL and DB designed the study, analyzed the data, and composed, edited,
and approved the manuscript. HB generated and tested the transgene
construct, reviewed the data, and helped to draft and edit the manuscript.
SF managed the transgenic mouse colony and animal imaging, compiled
the imaging data, analyzed transgene expression, analyzed the data, and
helped draft the manuscript. CR analyzed luciferase activities ex vivo,
Fromholt et al. Alzheimer's Research & Therapy  (2016) 8:36 Page 6 of 7
analyzed the data, and helped draft the manuscript. All authors read and
approved the final manuscript.
Competing interests
The authors declare that they have no competing interests.
Consent for publication
All authors have given consent for publication.
Ethical approval and consent to participate
All procedures involving mice were reviewed and approved by the University
of Florida Institutional Animal Care and Use Committee (Protocol Number
201506642). No human research subjects were involved in this study.
Author details
1Department of Neuroscience, Center for Translational Research in
Neurodegenerative Disease, University of Florida, Gainesville, FL, USA.
2McKnight Brain Institute, University of Florida, Gainesville, FL 32610, USA.
Received: 6 May 2016 Accepted: 26 July 2016
References
1. Dickson DW, Kouri N, Murray ME, Josephs KA. Neuropathology of
frontotemporal lobar degeneration-tau (FTLD-tau). J Mol Neurosci.
2011;45:384–9.
2. Forte A, Cipollaro M, Cascino A, Galderisi U. Small interfering RNAs and
antisense oligonucleotides for treatment of neurological diseases.
Curr Drug Targets. 2005;6:21–9.
3. Gonzalez-Alegre P. Therapeutic RNA, interference for neurodegenerative
diseases: From promise to progress. Pharmacol Ther. 2007;114:34–55.
4. Boudreau RL, Davidson BL. RNAi therapeutics for CNS disorders. Brain Res.
2010;1338:112–21.
5. Sah DW, Aronin N. Oligonucleotide therapeutic approaches for Huntington
disease. J Clin Invest. 2011;121:500–7.
6. Rodriguez-Lebron E, Denovan-Wright EM, Nash K, Lewin AS, Mandel RJ.
Intrastriatal rAAV-mediated delivery of anti-huntingtin shRNAs induces
partial reversal of disease progression in R6/1 Huntington’s disease
transgenic mice. Mol Ther. 2005;12:618–33.
7. DiFiglia M, Sena-Esteves M, Chase K, Sapp E, Pfister E, Sass M, et al.
Therapeutic silencing of mutant huntingtin with siRNA attenuates striatal
and cortical neuropathology and behavioral deficits. Proc Natl Acad Sci
U S A. 2007;104:17204–9.
8. Boudreau RL, McBride JL, Martins I, Shen S, Xing Y, Carter BJ, et al.
Nonallele-specific silencing of mutant and wild-type huntingtin
demonstrates therapeutic efficacy in Huntington’s disease mice. Mol Ther.
2009;17:1053–63.
9. Rodriguez-Lebron E, Gouvion CM, Moore SA, Davidson BL, Paulson HL.
Allele-specific RNAi mitigates phenotypic progression in a transgenic model
of Alzheimer’s disease. Mol Ther. 2009;17:1563–73.
10. Nelson PT, Braak H, Markesbery WR. Neuropathology and cognitive
impairment in Alzheimer disease: a complex but coherent relationship.
J Neuropathol Exp Neurol. 2009;68:1–14.
11. Golde TE, Dickson D, Hutton M. Filling the gaps in the abeta cascade
hypothesis of Alzheimer’s disease. Curr Alzheimer Res. 2006;3:421–30.
12. Golde TE, Petrucelli L, Lewis J. Targeting Abeta and tau in Alzheimer’s
disease, an early interim report. Exp Neurol. 2010;223:252–66.
13. Haugarvoll K, Wszolek ZK, Hutton M. The genetics of frontotemporal
dementia. Neurol Clin. 2007;25:697–715.
14. Ganjei JK. Targeting amyloid precursor protein secretases: Alzheimer’s
disease and beyond. Drug News Perspect. 2010;23:573–84.
15. Seabrook GR, Ray WJ, Shearman M, Hutton M. Beyond amyloid: the next
generation of Alzheimer’s disease therapeutics. Mol Interv. 2007;7:261–70.
16. DeVos SL, Goncharoff DK, Chen G, Kebodeaux CS, Yamada K, Stewart FR, et
al. Antisense reduction of tau in adult mice protects against seizures.
J Neurosci. 2013;33:12887–97.
17. Dubourg C, Sanlaville D, Doco-Fenzy M, Le Caignec C, Missirian C, Jaillard S,
et al. Clinical and molecular characterization of 17q21.31 microdeletion
syndrome in 14 French patients with mental retardation. Eur J Med Genet.
2011;54:144–51.
18. Sapir T, Frotscher M, Levy T, Mandelkow EM, Reiner O. Tau’s role in the
developing brain: implications for intellectual disability. Hum Mol Genet.
2012;21:1681–92.
19. Kimura T, Whitcomb DJ, Jo J, Regan P, Piers T, Heo S, et al. Microtubule-
associated protein tau is essential for long-term depression in the
hippocampus. Philos Trans R Soc Lond B Biol Sci. 2013;369:20130144.
20. Roberson ED, Scearce-Levie K, Palop JJ, Yan F, Cheng IH, Wu T, et al.
Reducing endogenous tau ameliorates amyloid beta-induced deficits in an
Alzheimer’s disease mouse model. Science. 2007;316:750–4.
21. Jankowsky JL, Slunt HH, Gonzales V, Savonenko AV, Wen JC, Jenkins NA, et
al. Persistent amyloidosis following suppression of Abeta production in a
transgenic model of Alzheimer disease. PLoS Med. 2005;2:e355.
22. Jankowsky JL, Slunt HH, Gonzales V, Jenkins NA, Copeland NG, Borchelt DR.
APP processing and amyloid deposition in mice haplo-insufficient for
presenilin 1 5. Neurobiol Aging. 2004;25:885–92.
23. SantaCruz K, Lewis J, Spires T, Paulson J, Kotilinek L, Ingelsson M, et al. Tau
suppression in a neurodegenerative mouse model improves memory
function. Science. 2005;309:476–81.
24. Mansuy IM, Winder DG, Moallem TM, Osman M, Mayford M, Hawkins RD, et
al. Inducible and reversable gene expression with the rtTA system for the
study of memory. Neuron. 1998;21:257–65.
25. Yamada K, Holth JK, Liao F, Stewart FR, Mahan TE, Jiang H, et al. Neuronal
activity regulates extracellular tau in vivo. J Exp Med. 2014;211:387–93.
•  We accept pre-submission inquiries 
•  Our selector tool helps you to find the most relevant journal
•  We provide round the clock customer support 
•  Convenient online submission
•  Thorough peer review
•  Inclusion in PubMed and all major indexing services 
•  Maximum visibility for your research
Submit your manuscript at
www.biomedcentral.com/submit
Submit your next manuscript to BioMed Central 
and we will help you at every step:
Fromholt et al. Alzheimer's Research & Therapy  (2016) 8:36 Page 7 of 7
